Fidaxomicin more cost effective than vancomycin in patients with cancer infected with clostridium difficile
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), patients with cancer who become infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin compared with vancomycin, the current standard of care.
Clostridium dificile infection (CDI) can often present in patients received chemotherapy. In addition, those with solid cancers can be more susceptible to CDI than those with liquid tumors due to longer hospital admissions and increased antibiotic exposure and anti-cancer agents. When antibiotics alter a patient's gut flora and destroy many bacteria that live in the gut, clostridium dificile is given the chance to multiply and cause infection, thus causing diarrhea requiring antibiotics with gram-positive anaerobic coverage.
The most common agents used to treat CDI are metronidazole, oral vancomycin, and fidaxomicin, but treatment depends on severity of the infection. Multiple courses of oral vancomycin can be expensive for patients, and this decision-tree analysis demonstrates that fidaxomicin for the treatment of CDI in patients with cancer can reduce healthcare spending while maintaining effectiveness compared with vancomycin.
Those infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin.
New data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) show that overall treatment costs for cancer patients with clostridium difficile infection (CDI), based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of €5,600 per patient.
Patients who have received chemotherapy and those with solid tumours can be particularly susceptible to CDI due to their long hospital stays and exposure to many antibiotics and chemotherapeutic agents. These patients are also prone to recurrent episodes of CDI.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|